---
title: "Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK)"
description: "Merck & Co., Inc. (NYSE:MRK) experienced a significant surge in put options trading, with 177,669 options purchased, marking a 341% increase from the average daily volume. The stock price fell by 1.5%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/228248824.md"
published_at: "2025-02-13T22:06:41.000Z"
---

# Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK)

> Merck & Co., Inc. (NYSE:MRK) experienced a significant surge in put options trading, with 177,669 options purchased, marking a 341% increase from the average daily volume. The stock price fell by 1.5% to $84.35, with a trading volume of over 20 million shares. Merck's recent quarterly earnings showed a revenue of $15.62 billion, slightly above estimates, but EPS missed expectations. The company also announced a $10 billion share repurchase program and a quarterly dividend of $0.81, reflecting confidence in its stock value.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was the recipient of unusually large options trading on Thursday. Traders acquired 177,669 put options on the company. This represents an increase of approximately 341% compared to the average volume of 40,313 put options.

Get **Merck & Co., Inc.** alerts:

## Merck & Co., Inc. Trading Down 1.5 %

-   Merck: 4 No-Brainer Reasons to Buy This Dip

Shares of MRK stock traded down $1.32 on Thursday, hitting $84.35. The stock had a trading volume of 20,375,205 shares, compared to its average volume of 14,421,404. The company's 50 day moving average price is $97.82 and its 200-day moving average price is $105.65. Merck & Co., Inc. has a 1 year low of $84.31 and a 1 year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm has a market capitalization of $213.37 billion, a P/E ratio of 12.53, a P/E/G ratio of 0.83 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). The business had revenue of $15.62 billion during the quarter, compared to analyst estimates of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business's revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.03 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

-   Moderna Shares Spike on H5N1 News—What’s Next for Investors?

Merck & Co., Inc. announced that its board has authorized a share repurchase program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

## Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date is Monday, March 17th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 48.14%.

## Wall Street Analysts Forecast Growth

-   MarketBeat Week in Review – 11/4 - 11/8

Several research analysts have recently weighed in on the stock. Daiwa America cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 11th. TD Securities lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price target for the company from $121.00 to $100.00 in a report on Monday. UBS Group decreased their price objective on Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets reduced their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and an average target price of $117.06.

**View Our Latest Report on MRK**

## Insiders Place Their Bets

In other news, Director Inge G. Thulin bought 2,833 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was acquired at an average cost of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now owns 2,933 shares of the company's stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares in the company, valued at $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company's stock.

## Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. E&G Advisors LP raised its position in Merck & Co., Inc. by 0.7% in the 3rd quarter. E&G Advisors LP now owns 14,698 shares of the company's stock valued at $1,669,000 after purchasing an additional 100 shares during the last quarter. Massachusetts Wealth Management increased its stake in Merck & Co., Inc. by 0.4% in the third quarter. Massachusetts Wealth Management now owns 22,474 shares of the company's stock valued at $2,552,000 after purchasing an additional 100 shares during the period. Shayne & Jacobs LLC raised its holdings in shares of Merck & Co., Inc. by 1.8% in the third quarter. Shayne & Jacobs LLC now owns 5,611 shares of the company's stock valued at $637,000 after buying an additional 100 shares during the last quarter. Alan B Lancz & Associates Inc. boosted its stake in shares of Merck & Co., Inc. by 0.7% during the third quarter. Alan B Lancz & Associates Inc. now owns 13,834 shares of the company's stock worth $1,571,000 after buying an additional 100 shares during the period. Finally, First Bank & Trust boosted its stake in shares of Merck & Co., Inc. by 1.1% during the third quarter. First Bank & Trust now owns 8,995 shares of the company's stock worth $1,021,000 after buying an additional 101 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

## Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

## Read More

-   Five stocks we like better than Merck & Co., Inc.
-   Learn Technical Analysis Skills to Master the Stock Market
-   Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
-   What Investors Need to Know to Beat the Market
-   Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
-   How to Invest in Blue Chip Stocks
-   Buffett Buys More Occidental Petroleum—Sticking to His Playbook

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

## Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSA Capital Partners LLP 增加了對默克公司（Merck & Co., Inc.）股票的持有量 $MRK | GSA Capital Partners LLP 在第三季度將其在默克公司的股份增加了 107.8%，目前持有 24,809 股，價值 208 萬美元。其他機構投資者也增加了他們的持股。內部人士的銷售包括首席醫學官 Chirfi Guind | [Link](https://longbridge.com/en/news/276119315.md) |
| 默克獲得 FDA 批准，Keytruda 聯合療法用於治療卵巢癌 | 默沙東已獲得 FDA 批准，將 Keytruda 和 Keytruda Qlex 與紫杉醇聯合用於治療鉑耐藥性卵巢癌。該批准基於 III 期 KEYNOTE-B96 試驗數據，顯示 PD-L1 表達腫瘤患者在無進展生存期和總體生存期方面有顯 | [Link](https://longbridge.com/en/news/275742611.md) |
| 特斯拉首輛 Cybercab 下線：沒有方向盤和踏板的汽車終於來了 | 特斯拉宣佈，首輛賽博無人駕駛電動車 Tesla Cybercab 在美國得州超級工廠正式下線。風險提示及免責條款 市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、 | [Link](https://longbridge.com/en/news/276188665.md) |
| 摩爾線程快速完成對 Qwen3.5 模型全面適配 | 摩爾線程宣佈已在旗艦級 AI 訓推一體全功能 GPU MTT S5000 上完成對阿里最新大模型 Qwen3.5 的全方位適配。此次支持充分展示了摩爾線程 MUSA 生態的成熟度與完備性，開發者可通過 MUSA C 編程語言及 Triton | [Link](https://longbridge.com/en/news/276153560.md) |
| 加拿大宣佈新國防工業戰略，注重國內製造以重獲戰備能力 | 加拿大總理卡尼於 2 月 17 日宣佈新的國防工業戰略，設定未來十年目標，包括將 70% 的國防合同授予本國企業，旨在實現國內採購和維護大部分軍事裝備。 | [Link](https://longbridge.com/en/news/276178964.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
